Zynex Faces Class Action Lawsuit Over Alleged Securities Fraud and Bankruptcy Issues

Zynex Faces Legal Challenges: A Class Action Lawsuit Unfolds

In a shocking turn of events, Zynex, Inc. (Ticker: ZYXI / ZYXIQ) is currently facing a securities class action lawsuit led by the prominent national shareholder rights law firm Hagens Berman. This legal action comes in the wake of the company's Chapter 11 bankruptcy filing and its subsequent delisting from major stock exchanges, ultimately triggered by revelations of a sprawling overbilling scheme that has left investors reeling.

The lawsuit, formally identified as Beidel v. Sandgaard, et al., was filed in the U.S. District Court for the District of Colorado. Hagens Berman is adamant that they are seeking restitution for all investors who bought Zynex securities between February 25, 2021, and December 15, 2025, during what they have termed the 'Class Period.' Investors are urged to act quickly as the firm has set a deadline of April 21, 2026, for individuals wanting to step forward as Lead Plaintiffs.

Allegations at the Heart of the Lawsuit

Hagens Berman's investigation into Zynex has revealed allegations of fundamental market deception, particularly surrounding the source of the company's revenues. Reed Kathrein, a partner at the firm leading the investigation, has stated, "The allegations imply that Zynex's touted growth was not a reflection of genuine market demand, but rather the result of a predatory strategy that involved excessive supply distribution aimed at defrauding insurers."

Systemic Overbilling and Supply Manipulators

The crux of the lawsuit revolves around allegations that Zynex engaged in systemic overbilling practices. The company reportedly shipped an excessive number of medical supplies to patients—sometimes as many as 128 electrode pairs each month—regardless of actual medical necessity. This manipulation was allegedly orchestrated to artificially inflate billings sent to both government and private payors. Furthermore, the lawsuit posits that Zynex lacked sufficient internal controls to curb such widespread abuse of supply orders and billing discrepancies.

In a significant development, the lawsuit indicates that Zynex's largest client, Tricare, suspended all payments to the company in early 2025. The complaint alleges that Zynex's management concealed the severity of this suspension from investors, ultimately leading to the company agreeing to forfeit more than $85 million as a settlement for the fraud allegations.

Personnel Indictments and Diminishing Value

Multiple twists awaited Zynex as former CEO Thomas Sandgaard and former COO Anna Lucsok faced criminal indictments on January 21, 2026, for their roles in healthcare and securities fraud. Following these revelations, the company was compelled to file for Chapter 11 bankruptcy and was subsequently delisted from Nasdaq, leading to devastating financial losses for shareholders.

Crucial Next Steps for Investors

Investors who have suffered financial losses during the specified Class Period must act promptly. By submitting their losses, they may join the collective action against Zynex, with the deadline for requesting Lead Plaintiff status looming on April 21, 2026. Prospective plaintiffs can obtain more information and guidance on how to navigate this complex legal landscape by visiting the designated Hagens Berman website.

For those familiar with non-public information about Zynex, whistleblowers are encouraged to consider their options to assist in the ongoing investigation. The SEC Whistleblower program could potentially reward whistleblowers with up to 30% of any successful recovery, emphasizing the importance of accountability within corporate activities.

About Hagens Berman

Hagens Berman is well-regarded for its commitment to holding corporations accountable for their misconduct. With a history of securing over $2.9 billion for investors and other affected parties, the firm's focus on complex litigation positions it as a key player in corporate accountability. To stay informed about updates and continued developments regarding Zynex and similar cases, interested parties can follow Hagens Berman on social media.

For more information or assistance, investors may reach out to Reed Kathrein directly. Hagens Berman remains dedicated to seeing justice served for those impacted by Zynex's alleged wrongdoings.